BeyondPolio and InnoCentive Announce Winners of First Innovation Challenge in Support of Mission to Help Eradicate Polio

BeyondPolio and InnoCentive Announce Winners of First Innovation Challenge in
             Support of Mission to Help Eradicate Polio Globally

Crowdsourced Ideas from Five Solvers Identify Approaches to Making Delivery of
Noninfectious Polio Vaccine Easier and More Affordable

PR Newswire

WALTHAM, Mass., Nov. 13, 2012

WALTHAM, Mass., Nov. 13, 2012 /PRNewswire/ --InnoCentive, Inc., the global
leader in open innovation, crowdsourcing, and prize competitions, and
BeyondPolio, an initiative of the Jonas Salk Legacy Foundation and the
investment firm Spencer Trask, today announced the solutions of its first
Innovation Challenge which sought to identify ways to reduce the cost and
facilitate the use of the inactivated poliovirus vaccine (IPV) in low- and
middle-income countries. This Challenge achieved BeyondPolio's desired result
of identifying promising solution paths that could help complete the
eradication of polio at a global level, building on the success of the Global
Polio Eradication Initiative which has used oral poliovirus vaccine (OPV) to
nearly wipe out the virus in the remaining countries where it has been
circulating.

(Logo: http://photos.prnewswire.com/prnh/20120711/NE38133LOGO )

"One of the problems we face is that OPV continues to reintroduce potentially
paralyzing polioviruses in areas where it is used, since the vaccine contains
weakened viruses that can mutate back to a virulent form," said Dr. Peter
Salk, President of the Jonas Salk Legacy Foundation. "IPV, which is used in
over 50 wealthier countries, does not have that problem, but it is currently
unaffordable for widespread use in low- and middle-income countries. Reducing
its cost and making it easier to apply will go a long way toward helping push
poliovirus infection to extinction."

This successful Ideation Challenge asked participants to identify promising
approaches to significantly reducing the cost of using IPV in countries where
it is currently unaffordable.Over a two-month period, the Challenge attracted
432 Solvers and more than 50 solutions were submitted. Entries were reviewed
by experts in the field of polio research and eradication, and by Dr. Peter
Salk, son of Dr. Jonas Salk, the researcher who led the team that developed
IPV in the early 1950s.

Kevin Kimberlin, Chairman of Spencer Trask, added "We are delighted at the
level of interest our initial Challenge elicited and the creative ideas
proposed. InnoCentive's diverse Solver network has helped focus attention on
several promising approaches to reducing the cost of IPV and developing
affordable new noninfectious polio vaccines."

The following Solvers or Solver teams were selected as winners and each
received a $5,000 award. Two of the Solvers, Stephen Duren and Tiong Sun Chia,
learned of the Challenge through the Open Innovation Pavilion on nature.com,
which is powered by InnoCentive.

  oMicron Biomedical, LLC, Marietta, Georgia – Dissolving Microneedle Patches

  oHarvey Arbesman, M.D., Clinical Assistant Professor, Department of
    Dermatology, School of Medicine and Biomedical Sciences, University of
    Buffalo – Transcutaneous Adjuvant Patches

  oStephen Duren, graduate student, Department of Cell Biology, Microbiology
    and Molecular Biology, University of South Florida – Production of
    Poliovirus Antigens in Yeast

  oTiong Sun Chia, Ph.D. candidate, University of Western Australia at Perth
    – Production of Poliovirus Antigens in Plants

  oDmitriy S. Tipikin, Ph.D., Research Associate, Department of Radiology,
    Geisel School of Medicine at Dartmouth – Improvements to Traditional
    Poliovirus Vaccine Production Methods

Following the success of this initial Challenge, BeyondPolio is investigating
ways to accelerate development and testing of the proposed ideas. BeyondPolio
plans to conduct future Challenges and promote collaborative programs, and is
actively seeking partnerships with corporations, foundations and others who
can bring support, resources, and attention to enhance these efforts.

"InnoCentive is proud to be a part of this Challenge and its solutions, which
hold the promise of helping to eradicate polioviruses from the globe forever,"
said Dwayne Spradlin, CEO of InnoCentive. "Crowdsourcing ideas from across
geographies, disciplines, and specialties has proven time and again to be a
rapid and highly effective means of advancing innovative research into global
health issues."

About BeyondPolio
BeyondPolio is dedicated to assisting the global effort to eradicate polio and
maintain success once eradication is achieved. Our goal is to increase the
affordability and utilization of inactivated poliovirus vaccine (IPV) in the
final phases of the eradication effort and aid in the development of other
safe and affordable noninfectious poliovirus vaccines. We use collaborative
innovation programs and Challenges to focus attention, attract new people and
spur new creative approaches to this mission.

BeyondPolio is a collaborative program and designated fund of the Jonas Salk
Legacy Foundation, undertaken in conjunction with Spencer Trask & Co. The
Jonas Salk Legacy Foundation is a charitable organization under Section
501(c)(3) of the Internal Revenue Code, and donations to support this program
are deductible as charitable contributions to the extent permitted by law.

About InnoCentive
InnoCentive is the global leader in crowdsourcing innovation problems to the
world's smartest people who compete to provide ideas and solutions to
important business, social, policy, scientific, and technical challenges. Our
global network of millions of problem solvers, proven challenge methodology,
and cloud-based technology combine to help our clients transform their
economics of innovation through rapid solution delivery and the development of
sustainable open innovation programs. For more than a decade, leading
commercial, government, and nonprofit organizations such as AARP Foundation,
Booz Allen Hamilton, Cleveland Clinic, Eli Lilly & Company, EMC Corporation,
NASA, Nature Publishing Group, Procter & Gamble, Syngenta, The Economist, and
The Rockefeller Foundation have partnered with InnoCentive to rapidly generate
innovative new ideas and solve problems faster, more cost effectively, and
with less risk than ever before. For more information, visit
www.innocentive.com, email info@innocentive.com, or call 1-855-CROWDNOW (U.S.)
or +44 (0) 207 935 0827 (International).

Media Contacts:

Steve Bonadio
InnoCentive, Inc.
978-482-3300
sbonadio@innocentive.com

Marisa Borgasano
Schwartz MSL for InnoCentive
781-684-0770
innocentive@schwartzmsl.com

Kerry Safir
BeyondPolio
212-418-8556
ksafir@beyondpolio.org



SOURCE InnoCentive, Inc.

Website: http://www.innocentive.com
 
Press spacebar to pause and continue. Press esc to stop.